Genetically Modified Mesenchymal Stromal/Stem Cells: Application in Critical Illness.

Area of Science:

• Critical illness research
• Regenerative medicine
• Cell therapy

Background:

• Critical illnesses like sepsis and ARDS have high mortality and healthcare costs.
• Mesenchymal stem/stromal cells (MSCs) possess regenerative and immunomodulatory properties beneficial for critical conditions.
• Previous MSC therapy trials show mixed results, highlighting the need for optimization.

Purpose of the Study:

• To review strategies for enhancing MSC therapeutic potential in critical illnesses.
• To focus on genetic modification techniques for MSCs.
• To discuss implications for cell therapy in critical care.

Main Methods:

• Review of recent literature on genetically modified MSCs for critical illness.
• Emphasis on technologies for generating modified MSCs.
• Analysis of targeted genes, diseases, and therapeutic outcomes.

Main Results:

• Genetic modification offers a viable approach to improve MSC efficacy.
• Specific gene modifications can enhance MSC immunomodulatory and regenerative functions.
• Genetically engineered MSCs show potential in preclinical models of critical illness.

Conclusions:

• Genetic modification is a key strategy to optimize MSCs for critical illness treatment.
• Further research is needed to translate these findings into effective clinical therapies.
• Targeted genetic engineering holds promise for advancing MSC-based cell therapy.